For the Inventor, By the Inventor

Enter assignee name

Active Biotech Ab

USPTO Granted Patents = 43

% Expired Patents = 27.9

CIPO Patents = 3

EPO Patents = 18

Forward Citations = 551

Loading Chart...

Loading Chart...

74 inventors (with patents filed for the assignee):

Gunnar Hedlund (9 out of 13 patents)

Karl Erik Jansson (7 out of 13 patents)

Tomas Fex (6 out of 9 patents)

4. David Liberg (5 out of 8 patents)

5. Göran Forsberg (5 out of 7 patents)

6. Anders K Bjork (5 out of 13 patents)

7. Stephen East (4 out of 12 patents)

8. Helena Eriksson (4 out of 4 patents)

9. Marie Törngren (4 out of 4 patents)

10. Tomas Fristedt (4 out of 6 patents)

11. Hans Wännman (4 out of 4 patents)

12. Philip Huxley (3 out of 4 patents)

13. Dmitry Gabrilovich (3 out of 9 patents)

14. Stig Jonsson (3 out of 5 patents)

15. Colin MacKinnon (3 out of 3 patents)

Core Competencies:

Tasquinimod

Quinoline Derivatives

S100-Inhibitors

Immunomodulatory Compounds

Ocular Inflammatory Diseases

Superantigens

Combination Therapy

Eye Diseases

Crystalline Salts

Malignant Tumors

Pharmaceutical Compounds

Engineered Superantigens

43 patents: Sort by Forward Citations

1. 12582643 - Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy (2026-03-24),

2. 12485095 - Plurality of tasquinimod particles and use thereof (2025-12-02),

3. 12208091 - Compounds for treatment of eye diseases associated with excessive vascularisation (2025-01-28),

4. 11654140 - Treatment of ocular inflammatory diseases using laquinimod (2023-05-23),

5. 11478465 - Compounds for treatment of eye diseases associated with excessive vascularisation (2022-10-25),

6. 10385069 - Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors (2019-08-20),

7. 10314836 - Quinoline carboxamides for use in the treatment of multiple myeloma (2019-06-11),

8. 10300053 - Quinoline carboxamides for use in the treatment of leukemia (2019-05-28),

9. 10125125 - N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors (2018-11-13),

10. 9956212 - Quinoline carboxamides for use in the treatment of multiple myeloma (2018-05-01),

11. 9873687 - N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors (2018-01-23),

12. 9771372 - Compounds useful as S100-inhibitors (2017-09-26),

13. 9216956 - Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide (2015-12-22),

14. 8871936 - Method for manufacturing of quinoline-3-carboxamides (2014-10-28),

15. 8841421 - S100A9 interaction screening method (2014-09-23),

Company Overview

Active Biotech AB, based in Lund, Sweden, is a biotechnology company focused on developing innovative therapies for serious diseases. The company specializes in immunomodulatory compounds and has a strong emphasis on cancer treatment, particularly through its lead candidate, Tasquinimod. Active Biotech also explores therapeutic avenues for ocular inflammatory diseases and hyperproliferative conditions, leveraging its expertise in S100-inhibitors and quinoline carboxamides to address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

43 Patents

#13 in Lund

#165 in Sweden

#16,025 in the World

Active Biotech Ab

Forward Citations = 551

74 inventors:

Gunnar Hedlund (9 out of 13 patents)

Karl Erik Jansson (7 out of 13 patents)

Tomas Fex (6 out of 9 patents)

4. David Liberg (5 out of 8 patents)

5. Göran Forsberg (5 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Active Biotech Ab. Retrieved from https://idiyas.com/company/active-biotech-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…